Corcept Therapeutics Incorporated (CORT) Accused of Illicit Sales Practices In 2012, Corcept Therapeutics Incorporated (CORT) launched its prescription medicine Korlym, which served as Corcept’s only revenue-generating product. Due to the

HyreCar Inc. (HYRE) Materially Misstated its Insurance Reserves     A class action was filed on behalf of all persons and entities that purchased or otherwise acquired HyreCar Inc. (NASDAQ: HYRE)

The Boston Beer Company, Inc. (SAM) Failed to Disclose Deteriorating Sales, Inventory Write-offs, and Shortfall Fees     A shareholder filed a class action on behalf of all persons and entities

Spectrum Pharmaceuticals, Inc. (SPPI) Materially Misrepresented the Likelihood ROLONTIS Would be Approved by the FDA A class action was filed on behalf of all persons and entities that purchased or

Longeveron Inc. (LGVN) Materially Misrepresented the Viability of its Lead Product Lomecel-B Longeveron conducted its initial public offering (“IPO”) on February 12, 2021, issuing 2.66 million Class A shares at

Sesen Bio, Inc. (SESN) Hid Information About the Failure of its Clinical Trials for Vicineum On December 21, 2020, Sesen Bio announced it had submitted its Biologics License Application (“BLA”)

Waterdrop Inc. (WDH) Materially Misrepresented its Revenue Growth and Increased Customer Base in its IPO Documents   Waterdrop Inc. conducted its initial public offering (“IPO”) in May 2021. According to

Annovis Bio, Inc. (ANVS) Materially Misrepresented the Outcome of its ANVS401 Clinical Trials According to a class action complaint filed on behalf of Annovis Bio, Inc. shareholders, between May 21,

loanDepot, Inc. (LDI) Materially Misrepresented its Business Prospects in Connection with its IPO loanDepot, Inc. held its initial public offering (“IPO”) on February 16, 2021. The Registration Statement in connection